Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th August 2019
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell treatment a ‘breakthrough’ for equine lameness
“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage".
Arti-Cell Forte is the first stem cell-based medicine to receive marketing authorisation

The first stem cell-based medicine to receive marketing authorisation for the treatment of equine lameness has been launched by Boehringer Ingelheim.

Hailed as a ‘breakthrough medicine’ for degenerative joint disease in horses, Arti-Cell Forte is the first ‘ready-to-use’ stem cell-based product to be licensed in any veterinary species. It is also the only stem cell treatment to contain induced cells, marking a significant step in stem cell therapies and medicine as a whole.

“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage,” explained DR Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager.

“Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses. This makes Arti-Cell® Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease.”

The medicine is available to veterinary practitioners direct from Boehringer Ingelheim. It is stored at ultra-low temperatures to maintain its two-year shelf life, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately before injecting. 

Full training on storage and administration of the medicine is available from the Boehringer via face-to-face CPD at practice meetings or specific CPD events. For more information about these events, email vetenquiries@boehringer-ingelheim.com 

Become a member or log in to add this story to your CPD history

Rabbit Awareness Week set to return this summer

News Story 1
 Rabbit Awareness Week (RAW) is returning this summer, running from 24-28 June 2024. The theme for this year will be 'Healthy Diet, Happy Bunnies'.

The focus on rabbits' diet comes after the most recent PDSA Animal Wellbeing (PAW) Report report revealed that 42 per cent of veterinary professionals identified inappropriate diet as one of the five most important rabbit welfare issues that need to be address.

The campaign will include veterinary blogs, videos, and digital waiting room resources. Practices can sign up to receive updates about RAW. 

Click here for more...
News Shorts
CVS Group hit by cyber attack

CVS Group, which owns more than 450 veterinary practices in the UK, has been hit by a cyber attack.

In a statement, the group said the incident involved unauthorised external access to a limited number of its IT systems. As soon as the attack was discovered, the group took its IT systems temporarily offline, causing 'considerable operational disruption'.

It has warned that the security steps taken and ongoing plans to move its operational systems and IT infrastructure to the Cloud are likely to have an ongoing impact over a number of weeks.

Due to the risk that personal information was accessed, CVS has informed the Information Commissioner's Office. The company is working with third party consultants to investigate the incident.